Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition
| dc.rights.license | open | en_US |
| dc.contributor.author | SCHORETSANITIS, Georgios | |
| dc.contributor.author | ANIL YAĞCIOĞLU, A Elif | |
| dc.contributor.author | RUAN, Can-Jun | |
| dc.contributor.author | EAP, Chin B | |
| dc.contributor.author | MOLDEN, Espen | |
| dc.contributor.author | BAPTISTA, Trino | |
| dc.contributor.author | CLARK, Scott R | |
| dc.contributor.author | FERNANDEZ-EGEA, Emilio | |
| dc.contributor.author | KIM, Se Hyun | |
| dc.contributor.author | LANE, Hsien-Yuan | |
| dc.contributor.author | LEUNG, Jonathan | |
| dc.contributor.author | MAROÑAS AMIGO, Olalla | |
| dc.contributor.author | MOTUCA, Mariano | |
| dc.contributor.author | OLMOS, Ismael | |
| dc.contributor.author | EVERY-PALMER, Susanna | |
| dc.contributor.author | PROCYSHYN, Ric M | |
| dc.contributor.author | ROHDE, Christopher | |
| dc.contributor.author | SATISH, Suhas | |
| dc.contributor.author | SCHULTE, Peter F J | |
| dc.contributor.author | SPINA, Edoardo | |
| dc.contributor.author | TAKEUCHI, Hiroyoshi | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | VERDOUX, Helene | |
| dc.contributor.author | CORRELL, Christoph U | |
| dc.contributor.author | DE LEON, Jose | |
| dc.date.accessioned | 2023-09-27T14:21:57Z | |
| dc.date.available | 2023-09-27T14:21:57Z | |
| dc.date.issued | 2023-06-01 | |
| dc.identifier.issn | 1573-2509 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/183820 | |
| dc.description.abstractEn | During weak induction (from smoking and/or valproate co-prescription), clozapine ultrarapid metabolizers (UMs) need very high daily doses to reach the minimum therapeutic concentration of 350 ng/ml in plasma; clozapine UMs need clozapine doses higher than: 1) 900 mg/day in patients of European/African ancestry, or 2) 600 mg/day in those of Asian ancestry. Published clozapine UMs include 10 males of European/African ancestry, mainly assessed with single concentrations. Five new clozapine UMs (two of European and three of Asian ancestry) with repeated assessments are described. A US double-blind randomized trial included a 32-year-old male smoking two packages/day with a minimum therapeutic dose of 1,591 mg/day from a single TDM during open treatment of 900 mg/day. In a Turkish inpatient study, a 30-year-old male smoker was a possible clozapine UM needing a minimum therapeutic dose of 1,029 mg/day estimated from two trough steady-state concentrations on 600 mg/day. In a Chinese study, three possible clozapine UMs (all male smokers) were identified. The clozapine minimum therapeutic dose estimated with trough steady-state concentrations >150 ng/ml was: 1) 625 mg/day, based on a mean of 20 concentrations in Case 3; 2) 673 mg/day, based on a mean of 4 concentrations in Case 4; and 3) 648 mg/day, based on a mean of 11 concentrations in Case 5. Based on these limited studies, clozapine UMs during weak induction may account for 1-2% of clozapine-treated patients of European ancestry and <1% of those of Asian ancestry. A clozapine-to-norclozapine ratio <0.5 should not be used to identify clozapine UMs. | |
| dc.language.iso | EN | en_US |
| dc.title.en | Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition | |
| dc.title.alternative | Schizophr Res | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.schres.2023.05.010 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 37268453 | en_US |
| bordeaux.journal | Schizophrenia Research | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | pubmed | |
| hal.identifier | hal-04220135 | |
| hal.version | 1 | |
| hal.date.transferred | 2023-09-27T14:22:11Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| workflow.import.source | pubmed | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Schizophrenia%20Research&rft.date=2023-06-01&rft.eissn=1573-2509&rft.issn=1573-2509&rft.au=SCHORETSANITIS,%20Georgios&ANIL%20YA%C4%9ECIO%C4%9ELU,%20A%20Elif&RUAN,%20Can-Jun&EAP,%20Chin%20B&MOLDEN,%20Espen&rft.genre=article |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||